Share your opinion about this

Like
Comment
Favorite

L N Ramesh
2023-08-28

Share your opinion about this news…

Novocure falls after setback to Phase 3 trial for Tumor Treating Fields

NovoCure (NASDAQ:NVCR) lost ~39% pre-market Monday after the medical device maker announced that its cancer treatment, Tumor Treating Fields (TTFieds), didn't reach the main goal of overall survival (

Novocure falls after setback to Phase 3 trial for Tumor Treating Fields

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":213843038212352,"tweetId":"213843038212352","gmtCreate":1693225836103,"gmtModify":1693225845792,"author":{"id":4096514301867030,"idStr":"4096514301867030","authorId":4096514301867030,"authorIdStr":"4096514301867030","name":"L N Ramesh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Share your opinion about this news…</p></body></html>","htmlText":"<html><head></head><body><p>Share your opinion about this news…</p></body></html>","text":"Share your opinion about this news…","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/213843038212352","repostId":2362124728,"repostType":2,"repost":{"id":"2362124728","kind":"highlight","pubTimestamp":1693223658,"share":"https://www.laohu8.com/m/news/2362124728?lang=&edition=full","pubTime":"2023-08-28 19:54","market":"us","language":"en","title":"Novocure falls after setback to Phase 3 trial for Tumor Treating Fields","url":"https://stock-news.laohu8.com/highlight/detail?id=2362124728","media":"seekingalpha","summary":"NovoCure (NASDAQ:NVCR) lost ~39% pre-market Monday after the medical device maker announced that its cancer treatment, Tumor Treating Fields (TTFieds), didn't reach the main goal of overall survival (","content":"<html><body><ul> <li>NovoCure (<span>NASDAQ:NVCR</span>) <span>lost ~39%</span> pre-market Monday after the medical device maker announced that its cancer treatment, Tumor Treating Fields (TTFieds), didn't reach the main goal of overall survival (OS) in a Phase 3 trial.</li> <li>The ENGOT-ov50 / GOG-3029 / INNOVATE-3 study, designed to evaluate TTFields in combination<span> with chemotherapy paclitaxel in platinum-resistant ovarian cancer, had recruited 540 patients as of October 2021 when its enrollments closed.</span> </li> <li>According to its final data analysis, the patients on TTFields plus paclitaxel (n = 280) indicated a median OS of 12.2 months compared to 11.9 months of median OS in the paclitaxel-only arm (n = 278).</li> <li>The company said that the experimental therapy was well tolerated with no added systemic toxicities, in line with prior studies.</li> <li>However, citing an exploratory subgroup analysis, NovoCure (NVCR) stated that there was a clinical benefit for those who had previously received a single line of therapy.</li> <li>This finding \"suggests the potential for a clinical benefit when TTFields therapy is initiated early in a patient's treatment journey,\" Novocure's (NVCR) Executive Chairman William Doyle added. </li> </ul> <div> <h2>More on NovoCure</h2> <ul> <li><a href=\"https://laohu8.com/S/NVCR\">NovoCure Limited</a>: Record Losses, Falling Margins, And Downward Momentum</li> <li>NovoCure: Uncertain Regulatory Path And Slowing Growth</li> <li> NovoCure Limited (NVCR) Q2 2023 Earnings Call Transcript</li> <li>NovoCure Limited 2023 Q2 - Results - Earnings Call Presentation</li> <li>NovoCure upgraded at Piper Sandler ahead of Phase 3 readout for TTFieds</li> <li>NovoCure upgraded at Wedbush citing balanced risk-reward setup</li> <li>Why did NovoCure stock crash today? TTFields data</li> </ul> </div></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure falls after setback to Phase 3 trial for Tumor Treating Fields</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure falls after setback to Phase 3 trial for Tumor Treating Fields\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-28 19:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4006677-novocure-stock-falls-phase-3-ttfieds-trial-fails><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NovoCure (NASDAQ:NVCR) lost ~39% pre-market Monday after the medical device maker announced that its cancer treatment, Tumor Treating Fields (TTFieds), didn't reach the main goal of overall survival (...</p>\n\n<a href=\"https://seekingalpha.com/news/4006677-novocure-stock-falls-phase-3-ttfieds-trial-fails\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277229026/image_1277229026.jpg","relate_stocks":{"LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","BK4559":"巴菲特持仓","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4550":"红杉资本持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0109392836.USD":"富兰克林科技股A","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4512":"苹果概念","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4548":"巴美列捷福持仓","LU0444971666.USD":"天利全球科技基金","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","BK4515":"5G概念","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","BK4553":"喜马拉雅资本持仓","BK4571":"数字音乐概念","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4534":"瑞士信贷持仓","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","AAPL":"苹果","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","BK4566":"资本集团","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","BK4082":"医疗保健设备","LU0082616367.USD":"摩根大通美国科技A（dist）","LU0056508442.USD":"贝莱德世界科技基金A2","NVCR":"NovoCure Limited"},"source_url":"https://seekingalpha.com/news/4006677-novocure-stock-falls-phase-3-ttfieds-trial-fails","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2362124728","content_text":"NovoCure (NASDAQ:NVCR) lost ~39% pre-market Monday after the medical device maker announced that its cancer treatment, Tumor Treating Fields (TTFieds), didn't reach the main goal of overall survival (OS) in a Phase 3 trial. The ENGOT-ov50 / GOG-3029 / INNOVATE-3 study, designed to evaluate TTFields in combination with chemotherapy paclitaxel in platinum-resistant ovarian cancer, had recruited 540 patients as of October 2021 when its enrollments closed.  According to its final data analysis, the patients on TTFields plus paclitaxel (n = 280) indicated a median OS of 12.2 months compared to 11.9 months of median OS in the paclitaxel-only arm (n = 278). The company said that the experimental therapy was well tolerated with no added systemic toxicities, in line with prior studies. However, citing an exploratory subgroup analysis, NovoCure (NVCR) stated that there was a clinical benefit for those who had previously received a single line of therapy. This finding \"suggests the potential for a clinical benefit when TTFields therapy is initiated early in a patient's treatment journey,\" Novocure's (NVCR) Executive Chairman William Doyle added.    More on NovoCure  NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth  NovoCure Limited (NVCR) Q2 2023 Earnings Call Transcript NovoCure Limited 2023 Q2 - Results - Earnings Call Presentation NovoCure upgraded at Piper Sandler ahead of Phase 3 readout for TTFieds NovoCure upgraded at Wedbush citing balanced risk-reward setup Why did NovoCure stock crash today? TTFields data","news_type":1},"isVote":1,"tweetType":1,"viewCount":194,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":30,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}